- Published: October 3, 2022
- Updated: October 3, 2022
- University / College: The University of Texas Health Science Center at Houston
- Language: English
- Downloads: 31
A corrigendum on
Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation
by Bazzazi, H., Isenberg, J. S., and Popel, A. S. (2017). Front. Physiol. 8: 48. doi: 10. 3389/fphys. 2017. 00048
In the original article, there was a mistake in the legend for Figure 3 as published.
“ TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. Two nanometer TSP1 is added for 10 min followed by 40 min of 50 ng/ml VEGF…” The correct legend appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
“ TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. 2 nM TSP1 is added for 10 min followed by 40 min of 50 ng/ml VEGF…”
Incorrect Author Name
An author name was incorrectly spelled asJeffery S. Isenberg. The correct spelling isJeffrey S. Isenberg. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Text Correction
In the original article, there was an error on theIntroductionsection page 2, paragraph 3:
“…we set out here to interrogate potential mechanisms for the inhibition of VEGF/VEGFR2 signaling to ERK1/2 and calcium byTSP1/CD4interaction utilizing a detailed rule-based model of VEGF signaling to ERK1/2 and calcium…”
A correction has been made toIntroduction, paragraph 3:
“…we set out here to interrogate potential mechanisms for the inhibition of VEGF/VEGFR2 signaling to ERK1/2 and calcium byTSP1/CD47interaction utilizing a detailed rule-based model of VEGF signaling to ERK1/2 and calcium…”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
In the original article, there was an error on theConflict of Interest Statement:
“ JI serves as chair of the scientific advisoryboardsof Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO).”
A correction has been made toConflict of Interest Statement:
“ JI serves as chair of the scientific advisoryboardof Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Conflict of Interest Statement
JI serves as chair of the scientific advisory board of Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO).
The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
